vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and INSTEEL INDUSTRIES INC (IIIN). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $159.9M, roughly 1.1× INSTEEL INDUSTRIES INC). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.7%, a 8.6% gap on every dollar of revenue. On growth, INSTEEL INDUSTRIES INC posted the faster year-over-year revenue change (23.3% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-2.2M). Over the past eight quarters, INSTEEL INDUSTRIES INC's revenue compounded faster (12.0% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.
AMPH vs IIIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $159.9M |
| Net Profit | $24.4M | $7.6M |
| Gross Margin | 46.8% | 11.3% |
| Operating Margin | 19.4% | 6.0% |
| Net Margin | 13.3% | 4.7% |
| Revenue YoY | -1.8% | 23.3% |
| Net Profit YoY | -35.7% | 602.4% |
| EPS (diluted) | $0.51 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $159.9M | ||
| Q3 25 | $191.8M | $177.4M | ||
| Q2 25 | $174.4M | $179.9M | ||
| Q1 25 | $170.5M | $160.7M | ||
| Q4 24 | $186.5M | $129.7M | ||
| Q3 24 | $191.2M | $134.3M | ||
| Q2 24 | $182.4M | $145.8M | ||
| Q1 24 | $171.8M | $127.4M |
| Q4 25 | $24.4M | $7.6M | ||
| Q3 25 | $17.4M | $14.6M | ||
| Q2 25 | $31.0M | $15.2M | ||
| Q1 25 | $25.3M | $10.2M | ||
| Q4 24 | $38.0M | $1.1M | ||
| Q3 24 | $40.4M | $4.7M | ||
| Q2 24 | $37.9M | $6.6M | ||
| Q1 24 | $43.2M | $6.9M |
| Q4 25 | 46.8% | 11.3% | ||
| Q3 25 | 51.4% | 16.1% | ||
| Q2 25 | 49.6% | 17.1% | ||
| Q1 25 | 50.0% | 15.3% | ||
| Q4 24 | 46.5% | 7.3% | ||
| Q3 24 | 53.3% | 9.1% | ||
| Q2 24 | 52.2% | 10.6% | ||
| Q1 24 | 52.4% | 12.3% |
| Q4 25 | 19.4% | 6.0% | ||
| Q3 25 | 13.2% | 10.8% | ||
| Q2 25 | 24.2% | 11.0% | ||
| Q1 25 | 21.9% | 8.3% | ||
| Q4 24 | 24.2% | 1.1% | ||
| Q3 24 | 29.8% | 4.5% | ||
| Q2 24 | 30.3% | 6.0% | ||
| Q1 24 | 27.9% | 7.0% |
| Q4 25 | 13.3% | 4.7% | ||
| Q3 25 | 9.0% | 8.2% | ||
| Q2 25 | 17.8% | 8.4% | ||
| Q1 25 | 14.8% | 6.4% | ||
| Q4 24 | 20.4% | 0.8% | ||
| Q3 24 | 21.1% | 3.5% | ||
| Q2 24 | 20.8% | 4.5% | ||
| Q1 24 | 25.1% | 5.4% |
| Q4 25 | $0.51 | $0.39 | ||
| Q3 25 | $0.37 | $0.74 | ||
| Q2 25 | $0.64 | $0.78 | ||
| Q1 25 | $0.51 | $0.52 | ||
| Q4 24 | $0.74 | $0.06 | ||
| Q3 24 | $0.78 | $0.24 | ||
| Q2 24 | $0.73 | $0.34 | ||
| Q1 24 | $0.81 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $15.6M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $358.8M |
| Total Assets | $1.6B | $456.1M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $15.6M | ||
| Q3 25 | $276.2M | $38.6M | ||
| Q2 25 | $231.8M | $53.7M | ||
| Q1 25 | $236.9M | $28.4M | ||
| Q4 24 | $221.6M | $36.0M | ||
| Q3 24 | $250.5M | $111.5M | ||
| Q2 24 | $217.8M | $97.7M | ||
| Q1 24 | $289.6M | $83.9M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $358.8M | ||
| Q3 25 | $776.7M | $371.5M | ||
| Q2 25 | $757.5M | $356.2M | ||
| Q1 25 | $751.3M | $341.4M | ||
| Q4 24 | $732.3M | $331.6M | ||
| Q3 24 | $727.7M | $350.9M | ||
| Q2 24 | $713.3M | $346.0M | ||
| Q1 24 | $672.4M | $340.6M |
| Q4 25 | $1.6B | $456.1M | ||
| Q3 25 | $1.7B | $462.6M | ||
| Q2 25 | $1.6B | $471.9M | ||
| Q1 25 | $1.6B | $421.9M | ||
| Q4 24 | $1.6B | $404.7M | ||
| Q3 24 | $1.5B | $422.6M | ||
| Q2 24 | $1.5B | $414.6M | ||
| Q1 24 | $1.6B | $397.2M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-701.0K |
| Free Cash FlowOCF − Capex | $24.6M | $-2.2M |
| FCF MarginFCF / Revenue | 13.4% | -1.4% |
| Capex IntensityCapex / Revenue | 4.5% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.35× | -0.09× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $439.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-701.0K | ||
| Q3 25 | $52.6M | $-17.0M | ||
| Q2 25 | $35.6M | $28.5M | ||
| Q1 25 | $35.1M | $-3.3M | ||
| Q4 24 | $29.0M | $19.0M | ||
| Q3 24 | $60.0M | $16.2M | ||
| Q2 24 | $69.1M | $18.8M | ||
| Q1 24 | $55.3M | $1.4M |
| Q4 25 | $24.6M | $-2.2M | ||
| Q3 25 | $47.2M | $-18.7M | ||
| Q2 25 | $25.0M | $26.9M | ||
| Q1 25 | $24.4M | $-5.5M | ||
| Q4 24 | $16.6M | $16.3M | ||
| Q3 24 | $46.2M | $14.5M | ||
| Q2 24 | $63.1M | $15.5M | ||
| Q1 24 | $46.5M | $-580.0K |
| Q4 25 | 13.4% | -1.4% | ||
| Q3 25 | 24.6% | -10.6% | ||
| Q2 25 | 14.3% | 15.0% | ||
| Q1 25 | 14.3% | -3.5% | ||
| Q4 24 | 8.9% | 12.6% | ||
| Q3 24 | 24.1% | 10.8% | ||
| Q2 24 | 34.6% | 10.7% | ||
| Q1 24 | 27.1% | -0.5% |
| Q4 25 | 4.5% | 0.9% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 6.1% | 0.9% | ||
| Q1 25 | 6.3% | 1.4% | ||
| Q4 24 | 6.7% | 2.1% | ||
| Q3 24 | 7.2% | 1.3% | ||
| Q2 24 | 3.3% | 2.2% | ||
| Q1 24 | 5.1% | 1.5% |
| Q4 25 | 1.35× | -0.09× | ||
| Q3 25 | 3.03× | -1.17× | ||
| Q2 25 | 1.15× | 1.88× | ||
| Q1 25 | 1.39× | -0.32× | ||
| Q4 24 | 0.76× | 17.56× | ||
| Q3 24 | 1.48× | 3.48× | ||
| Q2 24 | 1.82× | 2.86× | ||
| Q1 24 | 1.28× | 0.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IIIN
| Welded Wire Reinforcement | $108.4M | 68% |
| PC Strand | $51.6M | 32% |
